(Q35116112)

6 August 2017

1 reference

title

Developmental and pediatric pharmacogenomics (English)

1 reference

6 August 2017

1 reference

J Steven Leeder

1

1 reference

6 August 2017

publication date

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

331-341

1 reference

Initial sequencing and analysis of the human genome

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Testing medications in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

21 January 2018

Teratology of retinoids

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Fetal effects of maternal drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Biochemical toxicology of chemical teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Placental drug transfer: Effects of gestational age and species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Distribution of components of the glutathione detoxification system across the human placenta after uncomplicated vaginal deliveries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes during development and differentiation in the human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Characterization and identification of steroid sulfate transporters of human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Clinical trials in children: problems and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Pharmacogenetics and pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Drug-metabolizing enzymes in ligand-modulated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Interactions between herbal medicines and prescribed drugs: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Environmental xenoestrogens, antiandrogens and disorders of male sexual differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Potential effects of certain persistent organic pollutants and endocrine disrupting chemicals on the health of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Chemoprevention: increased potential to bear fruit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

P450 genes: structure, evolution, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Expression of CYP2D6 in developing human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Delayed ontogenesis of CYP1A2 in the human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Recent advances in the pharmacogenomics of thiopurine methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Valproic acid hepatic fatalities. III. U.S. experience since 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Lamotrigine-associated rash: risk/benefit considerations in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

BioMOL: a computer-assisted biological modeling tool for complex chemical mixtures and biological processes at the molecular level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Treatment of asthma with drugs modifying the leukotriene pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Evolution of asthma through childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

The challenges of delivering pharmacogenomics into clinical pediatrics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Psychopharmacology for young children: clinical needs and research opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Trends in the prescribing of psychotropic medications to preschoolers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Ontogenic profile of some antioxidants and lipid peroxidation in human placental and fetal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Variation in induction of human placental CYP2E1: possible role in susceptibility to fetal alcohol syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Expression of organic anion transporting polypeptide E (OATP-E) in human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Treatment of newly diagnosed pediatric epilepsy: a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Rash in adult and pediatric patients treated with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

Trends in childhood asthma: prevalence, health care utilization, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2FPHGS.4.3.331.22693

10.1517/PHGS.4.3.331.22693

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference